StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.53−0.03 (-1.92%)

Close on Nov 17, 2026Market cap $297.61MP/E –Yield –

Altimmune operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Altimmune's operating income for the twelve months ending Jun 30, 2026 was -$100.23M. For fiscal 2025 it was -$94.49M. The highest annual figure on record is -$3.40M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$94.49M–
FY2024Dec 31, 2024-$103.17M–
FY2023Dec 31, 2023-$95.93M–
FY2022Dec 31, 2022-$87.74M–
FY2021Dec 31, 2021-$96.91M–
FY2020Dec 31, 2020-$54.80M–
FY2019Dec 31, 2019-$21.46M–
FY2018Dec 31, 2018-$42.83M–
FY2017Dec 31, 2017-$52.05M–
FY2016Dec 31, 2016-$11.09M–
FY2015Dec 31, 2015-$3.40M–
FY2014Dec 31, 2014-$10.19M–
FY2013Dec 31, 2013-$10.84M–
FY2012Dec 31, 2012-$6.27M–
FY2011Dec 31, 2011-$11.73M–
FY2010Dec 31, 2010-$23.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.23M–
Q1 FY2026Mar 31, 2026-$24.24M–
Q4 FY2025Dec 31, 2025-$28.89M–
Q3 FY2025Sep 30, 2025-$20.86M–
Q2 FY2025Jun 30, 2025-$22.92M–
Q1 FY2025Mar 31, 2025-$21.82M–
Q4 FY2024Dec 31, 2024-$24.87M–
Q3 FY2024Sep 30, 2024-$24.77M–
Q2 FY2024Jun 30, 2024-$26.75M–
Q1 FY2024Mar 31, 2024-$26.79M–
Q4 FY2023Dec 31, 2023-$33.62M–
Q3 FY2023Sep 30, 2023-$22.54M–
Q2 FY2023Jun 30, 2023-$18.01M–
Q1 FY2023Mar 31, 2023-$21.76M–
Q4 FY2022Dec 31, 2022-$23.09M–
Q3 FY2022Sep 30, 2022-$24.75M–
Q2 FY2022Jun 30, 2022-$20.40M–
Q1 FY2022Mar 31, 2022-$19.50M–
Q4 FY2021Dec 31, 2021-$23.99M–
Q3 FY2021Sep 30, 2021-$33.20M–
Q2 FY2021Jun 30, 2021-$24.86M–
Q1 FY2021Mar 31, 2021-$14.86M–
Q4 FY2020Dec 31, 2020-$10.75M–
Q3 FY2020Sep 30, 2020-$18.32M–
Q2 FY2020Jun 30, 2020-$18.42M–
Q1 FY2020Mar 31, 2020-$7.31M–
Q4 FY2019Dec 31, 2019-$4.31M–
Q3 FY2019Sep 30, 2019-$11.27M–
Q2 FY2019Jun 30, 2019-$3.55M–
Q1 FY2019Mar 31, 2019-$2.33M–
Q4 FY2018Dec 31, 2018-$27.35M–
Q3 FY2018Sep 30, 2018-$4.06M–
Q2 FY2018Jun 30, 2018-$5.44M–
Q1 FY2018Mar 31, 2018-$5.99M–
Q4 FY2017Dec 31, 2017-$12.56M–
Q3 FY2017Sep 30, 2017-$30.95M–
Q2 FY2017Jun 30, 2017-$4.01M–
Q1 FY2017Mar 31, 2017-$4.52M–
Q4 FY2016Dec 31, 2016-$5.51M–
Q3 FY2016Sep 30, 2016-$4.79M–

More Altimmune figures

See a number that looks wrong?